Lumos Capital Surpluse vs Net Working Capital Analysis
LUMO Stock | USD 2.45 0.05 2.00% |
Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Capital Surpluse and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.
Capital Surpluse vs Net Working Capital
Capital Surpluse vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Capital Surpluse account and Net Working Capital. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Lumos Pharma's Capital Surpluse and Net Working Capital is -0.13. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Capital Surpluse and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Lumos Pharma are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Capital Surpluse i.e., Lumos Pharma's Capital Surpluse and Net Working Capital go up and down completely randomly.
Correlation Coefficient | -0.13 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Capital Surpluse
Net Working Capital
Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 25th of May 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 484K | 874K | 1.0M | 671.3K | Depreciation And Amortization | 203K | 49K | 44K | 41.8K |
Lumos Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Lumos Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lumos Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
Short Long Term Debt Total | 1.2M | 319K | 557K | 233K | 6.6M | 6.9M | |
Other Current Liab | 10.2M | 5.9M | 4.2M | 6.2M | 5.9M | 5.9M | |
Total Current Liabilities | 11.8M | 6.5M | 5.1M | 6.7M | 7.0M | 11.8M | |
Total Stockholder Equity | 78.9M | 116.6M | 89.0M | 59.6M | 27.3M | 25.9M | |
Property Plant And Equipment Net | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
Net Debt | (89.3M) | (98.4M) | (94.3M) | (55.8M) | (28.5M) | (29.9M) | |
Retained Earnings | (334.0M) | (66.0M) | (96.4M) | (127.5M) | (161.5M) | (169.6M) | |
Accounts Payable | 475K | 244K | 612K | 275K | 890K | 845.5K | |
Cash | 90.5M | 98.7M | 94.8M | 56.0M | 35.1M | 33.3M | |
Non Current Assets Total | 2.4M | 584K | 635K | 283K | 603K | 572.9K | |
Non Currrent Assets Other | 735K | (584K) | (635K) | (283K) | (325.5K) | (341.7K) | |
Cash And Short Term Investments | 90.5M | 98.7M | 94.8M | 67.4M | 36.1M | 34.3M | |
Net Receivables | 824K | 26.3M | 128K | 223K | 210K | 199.5K | |
Common Stock Total Equity | 372K | 373K | 12K | 83K | 74.7K | 71.0K | |
Common Stock Shares Outstanding | 144.7K | 6.8M | 8.3M | 8.4M | 8.1M | 4.1M | |
Liabilities And Stockholders Equity | 96.8M | 129.0M | 100.3M | 72.3M | 40.6M | 38.6M | |
Non Current Liabilities Total | 6.9M | 6.1M | 6M | 6.2M | 6.3M | 6.0M | |
Other Current Assets | 3.0M | 3.5M | 4.7M | 4.4M | 3.7M | 6.2M | |
Other Stockholder Equity | 412.5M | 182.5M | 185.3M | 187.0M | 188.7M | 214.3M | |
Total Liab | 17.9M | 12.5M | 11.3M | 12.7M | 13.3M | 21.4M | |
Property Plant And Equipment Gross | 457K | 584K | 635K | 283K | 603K | 572.9K | |
Total Current Assets | 94.4M | 128.4M | 99.7M | 72.0M | 40.0M | 38.0M | |
Accumulated Other Comprehensive Income | (6.6M) | (7.0M) | (63.5M) | (129.0M) | 0.0 | (9K) | |
Short Term Debt | 1.1M | 319K | 352K | 233K | 282K | 519.9K | |
Common Stock | 373K | 374K | 83K | 82K | 81K | 77.0K | |
Net Tangible Assets | 78.9M | 116.6M | 89.0M | 59.6M | 68.5M | 104.9M | |
Retained Earnings Total Equity | (237.5M) | (291.0M) | (334.0M) | (66.0M) | (59.4M) | (62.4M) | |
Capital Surpluse | 389.8M | 407.2M | 414.0M | 182.5M | 209.9M | 293.4M | |
Property Plant Equipment | 1.6M | 335K | 635K | 283K | 254.7K | 242.0K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Lumos Stock analysis
When running Lumos Pharma's price analysis, check to measure Lumos Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lumos Pharma is operating at the current time. Most of Lumos Pharma's value examination focuses on studying past and present price action to predict the probability of Lumos Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lumos Pharma's price. Additionally, you may evaluate how the addition of Lumos Pharma to your portfolios can decrease your overall portfolio volatility.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
CEOs Directory Screen CEOs from public companies around the world | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Lumos Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.18) | Revenue Per Share 0.252 | Quarterly Revenue Growth 0.613 | Return On Assets (0.41) | Return On Equity (0.78) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.